238 related articles for article (PubMed ID: 29140230)
21. Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.
Lee KH; Lee JU; Ku NS; Jeong SJ; Han SH; Choi JY; Song YG; Kim JM
Yonsei Med J; 2017 Jul; 58(4):770-777. PubMed ID: 28540990
[TBL] [Abstract][Full Text] [Related]
22. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
Rokx C; Alshangi H; Verbon A; Zietse R; Hoorn EJ; Rijnders BJ
J Infect Dis; 2016 Feb; 213(4):561-8. PubMed ID: 26401025
[TBL] [Abstract][Full Text] [Related]
23. Long term renal function in Asian HIV-1 infected adults receiving tenofovir disoproxil fumarate without protease inhibitors.
Liegeon G; Harrison L; Nechba A; Halue G; Banchongkit S; Nilmanat A; Yutthakasemsunt N; Pathipvanich P; Thongpaen S; Lertkoonalak R; Althaus T; Lallemant M; Mary JY; Jourdain G
J Infect; 2019 Nov; 79(5):454-461. PubMed ID: 31401085
[TBL] [Abstract][Full Text] [Related]
24. HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study.
Jotwani V; Scherzer R; Estrella MM; Jacobson LP; Witt MD; Palella FJ; Macatangay B; Bennett M; Parikh CR; Ix JH; Shlipak MG
Am J Kidney Dis; 2016 Oct; 68(4):571-581. PubMed ID: 27287300
[TBL] [Abstract][Full Text] [Related]
25. Absence of Decline of Kidney Function in Human Immunodeficiency Virus-Infected Patients Under Routine Clinical Management.
Boucquemont J; Lawson-Ayayi S; Rigothier C; Bonnet F; Proust-Lima C; Neau D; Greib C; Miremont-Salamé G; Dabis F; Dupon M; Dauchy FA;
Nephron; 2017; 136(3):211-220. PubMed ID: 28445881
[TBL] [Abstract][Full Text] [Related]
26. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study.
Nyende L; Kalyesubula R; Sekasanvu E; Byakika-Kibwika P
BMC Nephrol; 2020 Jun; 21(1):232. PubMed ID: 32571236
[TBL] [Abstract][Full Text] [Related]
28. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
[TBL] [Abstract][Full Text] [Related]
29. Effects of long-term exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy on renal function in HIV-positive Chinese patients.
Tan Q; He YH; Yang TT; Yan DM; Wang Y; Zhao X; Liu HX; He SH; Zhou ZH
J Microbiol Immunol Infect; 2019 Oct; 52(5):710-719. PubMed ID: 31427111
[TBL] [Abstract][Full Text] [Related]
30. Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity.
Bonjoch A; Echeverría P; Perez-Alvarez N; Puig J; Estany C; Clotet B; Negredo E
Biomed Res Int; 2016; 2016():4380845. PubMed ID: 28078289
[No Abstract] [Full Text] [Related]
31. Acute Kidney Injury, Risk Factors, and Prognosis in Hospitalized HIV-Infected Adults in South Africa, Compared by Tenofovir Exposure.
Seedat F; Martinson N; Motlhaoleng K; Abraham P; Mancama D; Naicker S; Variava E
AIDS Res Hum Retroviruses; 2017 Jan; 33(1):33-40. PubMed ID: 27478997
[TBL] [Abstract][Full Text] [Related]
32. Design and methods of the prevalence and pharmacogenomics of tenofovir nephrotoxicity in HIV-positive adults in south-western Nigeria study.
Hassan MO; Duarte R; Mabayoje VO; Dickens C; Lasisi AO; Naicker S
BMC Nephrol; 2020 Oct; 21(1):436. PubMed ID: 33066744
[TBL] [Abstract][Full Text] [Related]
33. Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation.
Yoshino M; Yagura H; Kushida H; Yonemoto H; Bando H; Ogawa Y; Yajima K; Kasai D; Taniguchi T; Watanabe D; Nishida Y; Kuwahara T; Uehira T; Shirasaka T
J Infect Chemother; 2012 Apr; 18(2):169-74. PubMed ID: 21968965
[TBL] [Abstract][Full Text] [Related]
34. Tenofovir disoproxil fumarate-associated renal tubular dysfunction: noninvasive assessment of mitochondrial injury.
Samuels R; Bayerri CR; Sayer JA; Price DA; Payne BAI
AIDS; 2017 Jun; 31(9):1297-1301. PubMed ID: 28323756
[TBL] [Abstract][Full Text] [Related]
35. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
Grant PM; Kitch D; McComsey GA; Tierney C; Ha B; Brown TT
HIV Clin Trials; 2015; 16(2):66-71. PubMed ID: 25872972
[TBL] [Abstract][Full Text] [Related]
36. Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
Chikwapulo B; Ngwira B; Sagno JB; Evans R
Int J STD AIDS; 2018 Jun; 29(7):650-657. PubMed ID: 29334883
[TBL] [Abstract][Full Text] [Related]
37. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.
Hall AM; Edwards SG; Lapsley M; Connolly JO; Chetty K; O'Farrell S; Unwin RJ; Williams IG
Am J Kidney Dis; 2009 Dec; 54(6):1034-42. PubMed ID: 19783343
[TBL] [Abstract][Full Text] [Related]
38. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.
Hamzah L; Jose S; Booth JW; Hegazi A; Rayment M; Bailey A; Williams DI; Hendry BM; Hay P; Jones R; Levy JB; Chadwick DR; Johnson M; Sabin CA; Post FA
J Infect; 2017 May; 74(5):492-500. PubMed ID: 28130143
[TBL] [Abstract][Full Text] [Related]
39. Determinants of Risk Factors for Renal Impairment among HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate-Based Antiretroviral Regimen in Southern Vietnam.
Hoang CQ; Nguyen HD; Vu HQ; Nguyen KT; Hoang LT; Ly H; Tat TD; Phan LT
Biomed Res Int; 2020; 2020():7650104. PubMed ID: 32382572
[TBL] [Abstract][Full Text] [Related]
40. Medium-grade tubular proteinuria is common in HIV-positive patients and specifically associated with exposure to tenofovir disoproxil Fumarate.
Zeder AJ; Hilge R; Schrader S; Bogner JR; Seybold U
Infection; 2016 Oct; 44(5):641-9. PubMed ID: 27256076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
